医药产业链数据库之：创新药投融资，2025年1月全球和美国创新药VC、PE投融资环比改善

Investment Rating - The industry investment rating is "Outperform the Market - A" [6] Core Insights - The report indicates a significant improvement in the VC&PE financing of innovative drugs in both global and U.S. markets, with a continuous upward trend observed in January 2025 [1][4][15] - In 2024, the VC&PE financing for innovative drugs in global and U.S. markets has returned to positive growth, with year-on-year increases of 1.93% and 5.29% respectively, marking an improvement of 30.51 and 35.12 percentage points compared to 2023 [2][16] - The fourth quarter of 2024 saw a notable quarter-on-quarter improvement in VC&PE financing, with global and U.S. markets experiencing year-on-year growth of 19.65% and 11.72%, respectively, which is an increase of 21.06 and 23.94 percentage points from the previous quarter [3][20] - In January 2025, the financing growth rate continued to improve, with global and U.S. markets showing year-on-year increases of 42.43% and 27.51%, respectively, reflecting a month-on-month rise of 30.70 and 54.23 percentage points [4][28] Summary by Sections VC&PE Financing - January 2025 shows a clear improvement in VC&PE financing for innovative drugs in global and U.S. markets [1][4] - Annual observation for 2024 indicates a return to positive growth in VC&PE financing for innovative drugs [2][16] - Quarterly observation for Q4 2024 highlights significant improvements in financing growth rates [3][20] - Monthly observation for January 2025 confirms continued positive trends in financing growth [4][28]